Novartis charging in the race for generics

755968_blue_pillsThe big boys of pharmaceuticals are well on the generics wagon as Novartis announces the US introduction of Hecoria (tacrolimus) capsules, the first branded generic tacrolimus. The drug, which will be manufactured by Novartis' generics subsidiary #Sandoz, is a branded generic of the off-patent Prograf from Japanese drugmaker Astellas which had annual US sales approaching $1 billion. Hecoria is an approved drug used in the prevention of organ rejection in patients receiving liver or kidney transplants. Hecoria now offers a more affordable option to health care providers who wish to have their patients receive the same brand of tacrolimus at every prescription refill. Novartis through its Patient Assistance Program offers financial support to those most in need and has declared to offer the same commitment for Hecoria as for other branded Novartis products. While some pharmaceutical companies are still adamant not to join the generics race, there is no denying that the game is now changed.

To read more click here

To hear more about the generics debate click here to register for BioPharma Australasia which will on the 23rd to the 24th August, 2012 at the Swissotel, Sydney.

Leave a Reply

Your email address will not be published. Required fields are marked *